Puma Biotechnology
Puma Biotechnology's revenue fell 0.9% to $228 million in fiscal 2025. Its operating margin was 16.3%, up from 13.4% a year earlier. Free cash flow was $42 million, up 7.4%. The diluted share count rose 3.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Puma Biotechnology does
Puma Biotechnology is a drug company that sells one product, NERLYNX (neratinib), a pill for certain HER2-positive breast cancers. In the United States it is approved for early-stage disease after treatment with trastuzumab-based therapy, and, with another drug, for advanced or metastatic disease after prior treatments.
Puma sells NERLYNX in the United States through its own specialty sales force of approximately 35 sales specialists. Outside the United States it licenses the drug to other companies, which seek approval and sell it in their regions, including Europe, Canada, China and Australia. It earns money from its own sales and from these partners.
It also licensed alisertib from Takeda in September 2022. Alisertib is an experimental drug that blocks a protein called Aurora Kinase A, and Puma plans to test it first in small cell lung cancer and hormone receptor-positive breast cancer. Puma competes with other makers of HER2 breast cancer drugs, such as trastuzumab and tucatinib.
Its biggest risks, as it describes them
- It depends on a single product, NERLYNX, and has limited sales experience.
- It may not keep reporting profits.
- It may be unable to raise more money, and its loan terms limit what it can do.
- Alisertib is at an early stage and may fail in trials or approval.
- It relies on a small direct sales force to sell NERLYNX in the United States.
Income statement
From fiscal 2023 to 2025, earnings per share grew 16.4% a year and net income 20.0% a year, as new shares raised the share count by 7% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 70 | 46 | 49 | 87 | 92 |
| Debt incl. finance leases | 102 | 102 | 102 | 68 | 23 |
| Net debt (negative means net cash) | 32 | 56 | 53 | −19 | −69 |
| Net debt to EBITDA | 2.5x | 1.6x | 1.2x | −0.4x | −1.4x |
| Debt to equity | — | 4.7x | 1.9x | 0.7x | 0.2x |
| Interest coverage | 0.1x | 2.0x | 2.5x | 2.5x | 5.6x |
| Current ratio | 1.3x | 1.7x | 1.6x | 1.5x | 2.0x |
| Quick ratio | 1.2x | 1.7x | 1.5x | 1.4x | 1.9x |
Cash flow
Projections
Project Puma Biotechnology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Puma Biotechnology reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 8 of 9 |
| Rule of 40 | 14.7% | 14.7% | 17.4% |
| Altman Z'' | −16.14 | −16.73 | −14.13 |
| Accruals ratio | −2.4% | −3.9% | −5.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 6 of 9 | 5 of 9 | 8 of 9 |
Compare
Put Puma Biotechnology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Puma Biotechnology | FY25 | −0.9% | 16.3% | 18.3% | 48.2% | −1.4x | 8 | |
| IDEAYA Biosciences | FY25 | 3,024.4% | −72.8% | −33.6% | — | — | — | Compare |
| Harrow | FY25 | 36.4% | 11.2% | 15.8% | — | 5.5x | 6 | Compare |
| Rhythm Pharmaceuticals | FY25 | 45.8% | −101.2% | −61.5% | — | — | 6 | Compare |
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | 28 | 251 | 272 | 225 | 253 | 228 | 236 | 230 | 228 |
| Revenue growth | — | — | 806.6% | 8.5% | −17.3% | 12.5% | −9.9% | 3.3% | −2.2% | −0.9% |
| Gross profit | — | 22 | 216 | 235 | 186 | 190 | 173 | 173 | 166 | 170 |
| Research and development | 223 | 208 | 165 | 133 | 98 | 72 | 52 | 50 | 55 | 62 |
| Operating income | −277 | −292 | −95 | −39 | −30 | 1 | 24 | 33 | 31 | 37 |
| Net income | −276 | −292 | −114 | −76 | −60 | −29 | 0 | 22 | 30 | 31 |
| Diluted EPS (US$) | −8.29 | −7.85 | −2.99 | −1.95 | −1.52 | −0.72 | 0.00 | 0.45 | 0.62 | 0.61 |
| Diluted shares (millions) | 33 | 37 | 38 | 39 | 40 | 41 | 45 | 48 | 49 | 51 |
| Cash flow | ||||||||||
| Cash from operations | −142 | −172 | −24 | 22 | 1 | 21 | −16 | 27 | 39 | 42 |
| Capital expenditure | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −146 | −173 | −25 | 22 | 1 | 21 | −16 | 27 | 39 | 42 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 117 | 109 | 87 | 57 | 37 | 33 | 12 | 10 | 8 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 229 | 82 | 165 | 112 | 80 | 70 | 46 | 49 | 87 | 92 |
| Debt incl. finance leases | — | 48 | 152 | 95 | 84 | 102 | 102 | 102 | 68 | 23 |
| Total assets | 253 | 166 | 259 | 235 | 244 | 227 | 222 | 230 | 213 | 216 |
| Total liabilities | 43 | 112 | 225 | 217 | 250 | 229 | 200 | 177 | 121 | 86 |
| Shareholders' equity | 210 | 53 | 34 | 18 | −6 | −2 | 22 | 53 | 92 | 130 |
| Margins and ratios | ||||||||||
| Gross margin | — | 79.9% | 86.2% | 86.5% | 82.5% | 74.8% | 75.8% | 73.4% | 72.1% | 74.5% |
| Operating margin | — | −1,056.1% | −37.7% | −14.3% | −13.5% | 0.5% | 10.4% | 13.8% | 13.4% | 16.3% |
| Net margin | — | −1,054.6% | −45.2% | −27.8% | −26.6% | −11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| Free cash flow margin | — | −624.5% | −9.8% | 8.1% | 0.3% | 8.2% | −6.9% | 11.4% | 16.9% | 18.3% |
| Rule of 40 (growth + FCF margin) | — | — | 796.8% | 16.6% | −17.0% | 20.6% | −16.9% | 14.7% | 14.7% | 17.4% |
| Return on capital | — | — | — | — | — | — | 22.2% | 33.9% | 34.4% | 48.2% |
| Return on equity | −132.8% | −221.9% | −259.3% | −292.1% | — | — | — | 57.5% | 41.6% | 28.0% |
| Return on assets | −112.1% | −139.6% | −53.5% | −30.6% | −25.0% | −12.4% | 0.0% | 9.5% | 13.6% | 14.5% |
| Net debt to EBITDA | — | — | — | — | — | 2.5x | 1.6x | 1.2x | −0.4x | −1.4x |